BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

730 related articles for article (PubMed ID: 10067810)

  • 1. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
    Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
    Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women.
    Baron AT; Lafky JM; Suman VJ; Hillman DW; Buenafe MC; Boardman CH; Podratz KC; Perez EA; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1175-85. PubMed ID: 11700266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
    Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
    Sun LX; Wu Y; Han HQ; Wang QH
    Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the management of epithelial ovarian cancer.
    Berkenblit A; Cannistra SA
    J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer.
    Drenberg CD; Saunders BO; Wilbanks GD; Chen R; Nicosia RF; Kruk PA; Nicosia SV
    Gynecol Oncol; 2010 Apr; 117(1):117-24. PubMed ID: 20071014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients.
    Choi JH; Oh JY; Ryu SK; Kim SJ; Lee NY; Kim YS; Yi SY; Shim KS; Han WS
    Cancer; 1997 May; 79(10):1879-83. PubMed ID: 9149012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera.
    Baron AT; Lafky JM; Connolly DC; Peoples J; O'Kane DJ; Suman VJ; Boardman CH; Podratz KC; Maihle NJ
    J Immunol Methods; 1998 Oct; 219(1-2):23-43. PubMed ID: 9831386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer.
    Gadducci A; Ferdeghini M; Castellani C; Annicchiarico C; Gagetti O; Prontera C; Bianchi R; Facchini V
    Gynecol Oncol; 1995 Aug; 58(2):184-8. PubMed ID: 7542621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer.
    Petri AL; Høgdall E; Christensen IJ; Kjaer SK; Blaakaer J; Høgdall CK
    APMIS; 2006 May; 114(5):359-63. PubMed ID: 16725012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of serum transforming growth factor-alpha in patients of primary epithelial ovarian cancers by enzyme immunoassay.
    Chien CH; Huang CC; Lin YH; Shen J; Chow SN
    Gynecol Oncol; 1997 Sep; 66(3):405-10. PubMed ID: 9299253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer.
    Kolwijck E; Span PN; Thomas CM; Bulten J; Sweep FC; Massuger LF
    Oncol Rep; 2010 Feb; 23(2):579-84. PubMed ID: 20043124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study.
    Burger RA; Darcy KM; DiSaia PJ; Monk BJ; Grosen EA; Gatanaga T; Granger GA; Wang J; Tian C; Hanjani P; Cohn DE
    Cancer; 2004 Jul; 101(1):106-15. PubMed ID: 15221995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
    Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
    Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance.
    Kohler M; Janz I; Wintzer HO; Wagner E; Bauknecht T
    Anticancer Res; 1989; 9(6):1537-47. PubMed ID: 2697181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.